ΔΗΜΟΣΙΕΥΣΕΙΣ:

• N. Touroutoglou: Results of doctoral thesis are incorporated into the pharmacokinetics chapter in the German pharmacology textbook: pp. 30-34m W. Forth, D. Henschler, W. Rummel; Allgemeine and Spezielle Pharmakologie and Toxikologie, Wissenschaftsverlag, 5. Aufl. Mannheim, 1987

• Pfluger, T., Wendt, T., Touroutoglou, N.: Retrobulbar irradiation of endocrine opthalmopathy. A comparison between 10 and 16 Gy total dose. Strahlenther-Onkol 1990, 166(10)p 673-7

• N. Touroutoglou: M. Dimopoulos, A. Younes, Hess M., Cox, J., Cabanillas, F., Sarris, A.: Testicular Lymphoma: Late relapses and poor outcome despite doxorubicin based chemotherapy. J Clin Oncol 13, 6:1361-1367, 1995

• Touroutoglou, N.: Pazdur, R.: Thymidylate synthase inhibitors. Clin Cancer Res 2: 227-243, 1996

• Touroutoglou, N.: Clinical Results of a Pharmacodynamically-Based Strategy for Higher Dosign of Gemcitabine in Patients with Solid Tumors. Ann Oncol 9:1-6, 1998

• Treon, SP.., Hansen, M.,., Branagan, A., Verselis, S, Emmanouilides, C., Kimby, E, Frankel, SR., Touroutoglou, N, Turnbull,B Anderson, KC, Maloney, DG, Fox, EA. Polymorphisms in FC GAMMA RIIIA (CD16) Receptor Expression are Associated with Clinical Response to Rituximab in Waldenstrom’s Macroglobulinemia. J Clin Oncol 23 3:474-481, 2005.

POSTER PRESENTATION:

• Touroutoglou N, Von Horstig R, Kurz J, Shuhman G: The binding of anionic and cationic drugs to human tissues. Advances in Pharmacokinetics, Braunschweig 1986.

ΚΕΦΑΛΑΙΟ ΣΕ ΒΙΒΛΙΟ:

• Touroutoglou N, Arcenas A, Ajani J: Neuroendocrine, Tumors of the GI Tract. Medical Oncology: A Comprehensive Review, Second Edition. Richard Pazdur (Editor) PRR, Hyntington, NY, January 1996.

ABSTRACTS:

• Touroutoglou N, A Sarris, A. Younes, Dimopoulos M, Hess M, Cabanillas F. Testicular large cell lymphoma (TLCL): A retrospective study of 25 patients. Proc. Am. Soc. Clin. Oncol. 13:388, Abstr 1322, 1994.

• Pazdur R, Diaz-Canton E, Meyers C, Abbruzzese J, Patt Y, Rivera E, Touroutoglou, N, Edwards K, Bready B, Ajani JA: Phase II Trial of CI-980 in Metastatic Colorectal Carcinoma Patients. Proc. Am. Soc. Clin. Oncol. 14: A511, 1995.

• Lee J, Komaki R, Touroutoglou N, et al. Erythropoietin (EPO) prevents anemia during concurrent chemoradiation therapy (RT) for locally advanced inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998; 17:463a

• C. Emmanouilides, N. Touroutoglou, D. Diamandidis, L.Fayad, C. Wolf, M. Territo. Unrelated Allogenic Non-myeloablative Bone Marrow Transplant is feasible and effective. Proc. Am Soc Hem; 96:11, A5311, 2000

• Touroutoglou N, Wierman AM, Diamandidis D, Fayad L, Gollard R, Boedeker H, Nagy MN, Klimek S, Giron M, Nevada Cancer Center, Las Vegas NV. Neutrexin (TMTX), 5-Flourouracil (5FU) and Leucovorin (LCV), (NFL) in patients previously untreated with metastatic colorectal cancer (CRC). American Society of Clinical Oncology, May 2001.

• SP Treon, M Hansen, AR Branagan, C Emmanouilides, E Kimby, S Frankel, N Touroutoglou, D Maloney, KC Anderson, EA Fox. Polymorphisms in FcGRIIIA (CD!^) Receptor Expression are Associated with Clinical Response to Rituximab in Waldenstrom’s Macroglobulinemia. Proc. Am Soc. Clin Onc #6556, 2004

• Treon, SP., Fox, EA., Hansen, M., Verselis, S., Branagan, A., Touroutoglou, N., Maloney, DG., Frankel, SR., Anderson, KC., Emmanouilides, C., Kimby, E. Polymorphisms in FC GAMMA RIIIA (CD16) Receptor Expression are Associated with Clinical Response to Rituximab in Waldenstrom’s Macroglobulinemia. Blood 2002 Nov 16 100(11) p 2251